Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles

Biomaterials

Volumn 76, Issue , 2016, Pages 52-65

  Li, Jiahe ^a,c,d   Ai, Yiwei ^b   Wang, Lihua ^b   Bu, Pengcheng ^b   Sharkey, Charles C ^a   Wu, Qianhui ^a   Wun, Brittany ^a   Roy, Sweta ^a   Shen, Xiling ^b   King, Michael R ^a  

^a Cornell University   (United States)

^b Duke University   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH   (United States)

Author keywords

CTC; Metastasis; Platelets; Silica microparticles

Indexed keywords

BIOLOGICAL ORGANS; BIOMIMETICS; BLOOD; CARDIOVASCULAR SYSTEM; CELL DEATH; CYTOLOGY; DISEASES; PATHOLOGY; PLATELETS; SILICA; TUMORS;

CANCER HETEROGENEITIES; CIRCULATING TUMOR CELLS; FUNCTIONALIZED PARTICLES; METASTASIS; MICRO-PARTICLES; TARGETED DRUG DELIVERY; TUMOR MICROENVIRONMENT; TUMOR MICROENVIRONMENTS;

CELLS;

FIBRIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SILICA NANOPARTICLE; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOMIMETICS; CANCER CELL DESTRUCTION; CIRCULATING TUMOR CELL; COATED PARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; EXPERIMENTAL LUNG METASTASIS; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; HUMAN; HUMAN CELL; LUNG BLOOD VESSEL; MALE; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; THROMBOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; CELL MEMBRANE; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; PHAGOCYTOSIS; SECONDARY; THROMBOCYTE; TUMOR CELL LINE; TUMOR EMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CELL LINE, TUMOR; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASTIC CELLS, CIRCULATING; PHAGOCYTOSIS;

EID: 84960350950     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.046     Document Type: Article

References (39)

1. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nature reviews. Cancer 2006, 6(6):449-458.
2. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2(8):563-572.
3. Dawidczyk C.M., et al. State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. J. Control. Releas. Off. J. Control. Releas. Soc. 2014, 187C:133-144.
4. Bertrand N., et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66:2-25.
5. Li J., et al. Nanobiotechnology for the therapeutic targeting of cancer cells in blood. Cell. Mol. Bioeng. 2015, 1-14.
6. Chauhan V.P., Jain R.K. Strategies for advancing cancer nanomedicine. Nat. Mater. 2013, 12(11):958-962.
7. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 2013, 31(17). 2205-U210.
8. Placke T., et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012, 72(2):440-448.
9. Granot Z., et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20(3):300-314.
10. Gul N., et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Investig. 2014, 124(2):812-823.
11. Aerts J.G., Hegmans J.P. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013, 73(8):2381-2388.
12. Palumbo J.S., et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96(10):3302-3309.
13. BiggerstaffJ.P., et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin. Exp. Metastasis 1999, 17(8):723-730.
14. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 2014, 192(12):5451-5458.
15. Rizza P., Moretti F., Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010, 43(3):204-209.
16. Hejna M., Raderer M., Zielinski C.C. Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst. 1999, 91(1):22-36.
17. Amirkhosravi A., et al. Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Anticoagulants Antiplatelets Thrombolytics 2010, 663:241-259. second ed.
18. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27(48):6207-6215.
19. Mitchell M.J., et al. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(3):930-935.
20. Li J., Sharkey C.C., King M.R. Piperlongumine and immune cytokine TRAIL synergize to promote tumor death. Sci. Rep. 2015, 5:9987.
21. Zhang W., et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood 2012, 120(14):2889-2898.
22. Bubendorf L., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 2000, 31(5):578-583.
23. Minn A.J., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524.
24. Mazumder A., Rosenberg S.A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J. Exp. Med. 1984, 159(2):495-507.
25. Headrick J.R., et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann. Thorac. Surg. 2001, 71(3):975-979. discussion 979-80.
26. Labelle M., Begum S., Hynes R.O. Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes Metastasis. Cancer Cell 2011, 20(5):576-590.
27. Sobota A., et al. Binding of IgG-opsonized particles to Fc gamma R is an active stage of phagocytosis that involves receptor clustering and phosphorylation. J. Immunol. 2005, 175(7):4450-4457.
28. Martinez-Sales V., et al. Unstimulated and thrombin-stimulated platelets binding to immobilized fibrinogen and fibrin on polystyrene supports. Haemostasis 1995, 25(4):158-165.
29. Volkmann X., et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007, 46(5):1498-1508.
30. Zheng S.J., et al. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Investig. 2004, 113(1):58-64.
31. Erpenbeck L., Schon M.P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010, 115(17):3427-3436.
32. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11(2):123-134.
33. Modery-Pawlowski C.L., Gupta A.S. Heteromultivalent ligand-decoration for actively targeted nanomedicine. Biomaterials 2014, 35(9):2568-2579.
34. Modery-Pawlowski C.L., et al. A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms. Biomacromolecules 2013, 14(3):910-919.
35. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006, 1(3):297-315.
36. Oldenborg P.A., et al. Role of CD47 as a marker of self on red blood cells. Science 2000, 288(5473):2051.
37. Rodriguez P.L., et al. Minimal "self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339(6122):971-975.
38. van de Ven A.L., et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J. Control. Release 2012, 158(1):148-155.
39. Brown A.C., et al. Ultrasoft microgels displaying emergent platelet-like behaviours. Nat. Mater. 2014, 13(12):1108-1114.